Skip to main content

Texas Medical Center's Bill McKeon Lauds Innovation, Research at State of TMC

Published Oct 31, 2019 by Maggie Martin

Bill McKeon

Texas Medical Center President and CEO Bill McKeon discussed the positive trajectory of the world’s largest medical complex, which is being driven in large part by innovation, research and the expansion of existing institutions. McKeon delivered the annual State of TMC address in conjunction with the Greater Houston Partnership on October 31. 

In his keynote, McKeon gave a snapshot of the future of TMC, starting with developments happening at a few of TMC’s 61 member institutions. 

Texas A&M University, for instance, is partnering with Houston Methodist to build an innovative engineering medical school that will offer students the ability to earn a master’s degree or Ph.D. in engineering plus an M.D. 

“What’s happening at Texas A&M is powerful,” said McKeon. 

The project is expected to be completed by May 2020. 

McKeon also noted the University of Houston’s support of medical education with its new College of Medicine. In partnership with HCA Houston Healthcare, UH’s College of Medicine will provide residencies in Texas so graduates can continue to work in the state’s urban and rural communities. 

In addition to education programs, many of TMC’s member institutions continue to expand in Houston and across the station. That includes Texas Children's expansion in Austin over the past couple of years, as well as MD Anderson Cancer Center’s new campuses around the greater Houston region. 

McKeon explained that TMC’s reach extends beyond our region with its international BioBridge partnerships. The latest, signed with Denmark earlier this month, is a multi-faceted collaboration designed to bolster innovation in digital and telehealth. It also calls for increased emphasis on research and education. The agreement marks TMC’s third such international partnership with the goal of driving the next generation of health and medical advancements.  

“These BioBridges are really powerful. Why? Because we tie into the innovation community, and, in doing so, all the startups across the world are coming to the Texas Medical Center,” said McKeon. 

McKeon turned the stage over to Lance Black, associate director of the Texas Medical Center’s TMCx accelerator program, to lay out how innovation is driving growth at TMC.

“TMC Innovation Institute has become a magnet for global talent,” said Black. “We’re evolving to work more closely with our member institutions to better understand their needs.”

According to the Partnership's 2019 Houston Facts report, Texas Medical Center institutions employ more than 106,000 Houstonians, host more than 10 million patient visits a year and generate over $25 billion in direct economic impact.

The Texas Medical Center is internationally renowned as home to some of the leading minds in medicine, and thanks to its presence, Houston is at the forefront of advancing life sciences. 

The Partnership has been working very closely with Bill McKeon and his team to accelerate efforts to position Houston as the Third Coast for Life Sciences with a focus on developing a robust commercial life sciences industry here in Houston. 

There’s been great momentum made on this front, including the development of TMC3.

Set to open in 2022, this multi-institutional translational research campus will serve as the cornerstone for biomedical advancements in TMC and beyond. TMC3 will help drive economic growth, bringing more than $5 million into the Houston economy and creating roughly 30,000 jobs. It’ll also be instrumental in growing and advancing Houston’s innovation ecosystem, an area the Partnership has been intensely focused over the past couple of years. 

To see McKeon's full address, click here.

Learn more about Houston's biotechnology and life science sectors. Click here to learn more about health care in the Houston region

Related News

Life Sciences

MD Anderson, Rice University Launch New Collaborative to Advance Cancer Research

7/2/24
A new collaboration between The University of Texas MD Anderson Cancer Center and Rice University promises to drive industry growth and advance life-saving technologies through the newly established Cancer Bioengineering Collaborative. The initiative will help foster collaboration between the two institutions on fundamental and translational cancer research, develop new technologies for cancer detection and therapy, and secure external funding in support of further research and training. Rice researcher and Cancer Prevention and Research Institute of Texas (CPRIT) scholar Gang Bao and MD Anderson’s Dr. Jeffrey Molldrem will lead the hub.  “From fundamental discoveries in cancer science, tumor immunology and patient care to innovative engineering advances in drug delivery systems, nanostructures and synthetic biology, there is great potential for enabling cross-disciplinary collaboration to develop new technologies and approaches for detecting, monitoring and treating cancer,” Molldrem, chair of Hematopoietic Biology & Malignancy at MD Anderson, said in a release. “Our goal is to bridge the gap between bioengineering and cancer research to create transformative solutions that significantly improve patient outcomes.” The collaborative will also host monthly seminars focused on cancer bioengineering, annual retreats to highlight research and international leaders in cancer and bioengineering. Five research areas will be at the core of the hub’s work: Cell therapies: Developing more effective cell-based immunotherapies, including chimeric antigen receptor- and T cell receptor-based approaches. Nanotechnologies: Using nanoparticles for targeted cancer detection and therapy. Cancer vaccines: Incorporating advanced biomaterials, synthetic biology and nanoparticle delivery systems to develop therapeutic cancer vaccines. Artificial intelligence: Leveraging advanced computing tools for high-precision analysis of samples to identify new targets and inform therapeutic design. Molecular imaging: Deploying advanced molecular imaging techniques to enhance diagnostic and therapeutic tools. A seed grant program will also be established to fund research projects in the early stages of development. The partnership between Rice and MD Anderson is a testament to how the greater Houston region is committed to advancing the life sciences and biotech industry. The region has seen major new life science developments come online recently, including Levit Green, TMC Helix Park and The Alexandria Center for Advanced Technologies in The Woodlands.   
Read More
Life Sciences

The Woodlands Innovation District Aims to Attract Life Sciences Companies

6/28/24
A new district in The Woodlands hopes to expand on the area’s resurgence in life sciences developments.    Post pandemic, life sciences companies have been establishing facilities in The Woodlands, particularly along Research Forest Drive. And now, Developers Howard Hughes and Vitrian are building upon that growth by adding an additional 86.3 acres for future development, aiming to attract more biomanufacturing companies to the area. The duo has dubbed the area The Woodlands Innovation District.  “This joint venture further diversifies the innovative industries that are represented in The Woodlands with the advancement of life science,” said Jim Carman, President of the Houston Region for The Howard Hughes Corporation in a statement. “The Woodlands continues to attract companies from a variety of industries seeking a highly-skilled talent pool, business-friendly environment, and high quality of life for their employees.”  The district joins the area’s cluster of existing life sciences companies, such as Millipore Sigma and VGXI. Cellipont Bioservices, a San Diego-based cell therapy contract development and manufacturing organization, recently opened a 76,000-square-foot facility in the area. The facility is dedicated to cell therapies and serves as the company's new headquarters.  Cellipont’s move to the greater Houston region, announced in 2022, kickstarted a surge in life sciences activity in The Woodlands. Bionova Scientific, another California-based biotech company, recently announced plans to expand into the area, with a 100,000-square-foot manufacturing and research facility. The company, which produces materials used by cancer-fighting cell therapy companies, is expected to begin operations at the new location in 2025.  Nearby, Nurix Therapeutics, a clinical-stage biopharmaceutical company based in San Francisco, has relocated to the Alexandria Center for Advanced Technologies. This 12-acre life sciences campus, formerly the Lexicon Pharmaceuticals site, was inaugurated last year with support from Lexicon’s Founder and CEO and now Nurix's Chief Executive Officer, Arthur Sands. Backed by California-based real estate firm Alexandria Real Estate Equities, the campus is still being built out, with the goal of becoming a smaller version of The Texas Medical Center.   These recent developments have established The Woodlands as a leader in life sciences in the region. According to CBRE’s 2023 U.S. Life Sciences Outlook, The Woodlands accounted for 60% of the Houston region’s life sciences lease transactions in 2022.  The Woodlands Innovation District will encompass five sites, each providing tenant facilities ranging from 40,000 to over 200,000 square feet. These sites will offer build-to-suit shell spaces, anticipated to be move-in ready by Spring 2025.  Learn more about Houston’s life sciences and biotechnology industries. 
Read More

Related Events

Health Care

Life Sciences and Biotechnology Forum

Finding solutions to the problems that matter most is baked into Houston’s DNA. As the Third Coast for Life Sciences, the region’s world-class medical centers, research institutes and private companies are taking on…

Learn More
Learn More
Executive Partners